Blindness and neuropathy from diiodohydroxyquin-like drugs. Committee on drugs.
D000169:Acrodermatitis / Q000188:drug therapy; D000562:Amebiasis / Q000188:drug therapy; D001766:Blindness / Q000139:chemically induced*; D002648:Child; D002750:Chlorquinaldol / Q000633:toxicity; D007464:Clioquinol / Q000627:therapeutic use; D003967:Diarrhea / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004749:Entamoebiasis / Q000188:drug therapy; D006801:Humans; D004103:Iodoquinol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D007674:Kidney Diseases / Q000139:chemically induced*; D010372:Pediatrics; D010919:Placebos; D011804:Quinolines / Q000633:toxicity; D014792:Visual Acuity / Q000187:drug effects
D010919:Placebos; D011804:Quinolines; D004103:Iodoquinol; D007464:Clioquinol; D002750:Chlorquinaldol